Ligand Pharmaceuticals | LGND - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
Agenus USD 33.74M 468K 2026-03
Amgen USD 5.87B 1.02B 2026-03
Anika Therapeutics USD 19.18M 3.6M 2025-12
Arrowhead Research USD 75.25M 1.52M 2026-06
Baxter International USD 1.14B 251M 2026-06
Bristol-Myers Squibb USD 9.26B 1.19B 2026-06
Eli Lilly USD 16.22B 301.7M 2026-03
Enanta Pharmaceuticals -22.29M 23.75M 2024-12
Enviri Corporation USD 83.01M 37.46M 2025-12
Gilead Sciences USD 6.8B 1.29B 2026-06
GlaxoSmithKline GBP 6.51B 757M 2026-06
Glaxosmithkline GBP 5.75B 2.99B 2026-03
Heron Therapeutics USD 29.47M 3.17M 2025-12
Insmed USD 356.19M 99.73M 2026-06
Intrexon USD -297K 167K 2024-06
Ionis Pharmaceuticals USD 265M 22M 2026-06
Karyopharm Therapeutics USD 33.72M 1.13M 2026-03
Ligand Pharmaceuticals USD 100.41M 51.96M 2026-06
MacroGenics USD 11.24M 19.87M 2026-03
Merck USD 12.09B 1.24B 2026-03
Pacira USD 133.91M 7.27M 2026-06
Pfizer USD -248M 11.29B 2026-06
Rigel Pharmaceuticals USD 28.49M 7.01M 2024-06
Sangamo BioSciences -2.39M 1.09M 2024-06
Veracyte USD 108.55M 7.39M 2026-06